Literature DB >> 26971299

Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation.

Saskia Persoon1, Marie José Kersten2, Laurien M Buffart3, Griet Vander Slagmolen4, Joke W Baars5, Otto Visser6, Annelies Manenschijn7, Frans Nollet8, Mai J M Chinapaw9.   

Abstract

OBJECTIVES: We aimed to examine health-related physical fitness and its demographic and clinical correlates in patients recently treated with autologous stem cell transplantation.
DESIGN: Cross-sectional study.
METHODS: In 109 patients (multiple myeloma: n=58, lymphoma: n=51, median age: 55, range: 19-67 years) maximal exercise testing was conducted to assess cardiorespiratory fitness (VO2peak). Upper and lower extremity muscle strength were assessed with hand grip- and fixed dynamometry and body composition with whole body DXA scans. In addition, we assessed the patients' demographic and clinical characteristics and examined whether they were associated with health-related physical fitness.
RESULTS: VO2peak was 21.7 (5.5) mL/min/kg, 26% below reference values. Muscle strength was also reduced when compared with reference values (upper extremity: 90%, lower extremity: 80%) and 73% of our population was classified as overweight or obese. Being female and being older were significantly associated with a lower cardiorespiratory fitness (gender: β=-2.7, 95%CI=-4.6;-0.7mL/min/kg; age: β=-0.2, 95%CI=-0.3;-0.1mL/min/kg), upper (gender: β=-17.7, 95%CI=-20.1;-15.3kg; age: β=-0.2, 95%CI=-0.3;-0.1kg) and lower (gender: β=-58.3, 95%CI=-73.5;- 43.0Nm; age: β=-1.7, 95%CI=-2.4;-1.1Nm) extremity muscle strength. Patients who were non-smoking (β=-5.3, 95%CI=-8.7;-1.9), women (β=7.2, 95%CI=4.8;9.6) and diagnosed with multiple myeloma (β=4.6, 95%CI=2.2;6.9) had a higher percentage body fat.
CONCLUSIONS: The physical fitness deficits in this population indicate the need for targeted interventions. TRIAL REGISTRATION: Netherlands Trial Register - NTR2341.
Copyright © 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Body composition; Exercise tolerance; Hematology; Muscle strength

Mesh:

Year:  2016        PMID: 26971299     DOI: 10.1016/j.jsams.2016.01.006

Source DB:  PubMed          Journal:  J Sci Med Sport        ISSN: 1878-1861            Impact factor:   4.319


  5 in total

1.  Cardiorespiratory fitness and muscle strength in pancreatic cancer patients.

Authors:  Dorothea Clauss; Christine Tjaden; Thilo Hackert; Lutz Schneider; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf
Journal:  Support Care Cancer       Date:  2017-04-17       Impact factor: 3.603

2.  Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study.

Authors:  Johanna M van Dongen; Saskia Persoon; Gabrielle Jongeneel; Judith E Bosmans; Marie José Kersten; Johannes Brug; Frans Nollet; Mai J M Chinapaw; Laurien M Buffart
Journal:  J Cancer Surviv       Date:  2019-07-08       Impact factor: 4.442

3.  Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study.

Authors:  Rikke Faebo Larsen; Mary Jarden; Lisbeth Rosenbek Minet; Ulf Christian Frølund; Sören Möller; Niels Abildgaard
Journal:  BMC Cancer       Date:  2020-03-03       Impact factor: 4.430

Review 4.  The effect of exercise and nutrition interventions on physical functioning in patients undergoing haematopoietic stem cell transplantation: a systematic review and meta-analysis.

Authors:  Marianne C Prins; Gerben van Hinte; Niek Koenders; Anne Lieke Rondel; Nicole M A Blijlevens; Manon G A van den Berg
Journal:  Support Care Cancer       Date:  2021-06-16       Impact factor: 3.359

5.  Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation.

Authors:  S Persoon; M J M Chinapaw; L M Buffart; J Brug; M J Kersten; F Nollet
Journal:  Eur J Cancer Care (Engl)       Date:  2017-09-27       Impact factor: 2.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.